Search

Two second-year students -- Ellen Hukkelhoven and John Halliday -- were named Grayer Fellows for the 2010-2011 year.

… Saturday, May 1, 2010 Two second-year students were named Grayer Fellows for the 2010-2011 year. They are Ellen Hukkelhoven and John Halliday. These fellowships were established by Mr. and Mrs. Jonathan Grayer. Mr. Grayer is a member of the Gerstner Sloan Kettering Board of Trustees and the former chairman

An inherited mutation that contributes to lung cancer spread could be a target for therapies.

… Thursday, November 3, 2022 An inherited mutation in a gene called BRMS1 promotes lung cancer lung cancer metastasis.   The mutation could be targeted with therapies that prevent metastasis. Lung cancer is the leading cause of cancer death in the United States. The primary reason the disease is so deadly

Maria Jasin, PhD, a molecular biologist at the Sloan Kettering Institute, was named a recipient of the Shaw Prize in Life Science and Medicine. Dr. Jasin was recognized for her contributions to research showing that localized double-strand breaks in DNA stimulate recombination in mammalian cells.

… Tuesday, May 21, 2019 Maria Jasin, PhD , a molecular biologist at the Sloan Kettering Institute , was named a recipient of the Shaw Prize in Life Science and Medicine . Dr. Jasin was recognized for her contributions to research showing that localized double-strand breaks in DNA stimulate recombination

MSK physicians and scientists highlighted some of the institution’s latest advances in transplantation and cellular therapies at the Tandem Meetings held February 4 to 6, 2026, in Salt Lake City.

… Monday, April 6, 2026 Memorial Sloan Kettering Cancer Center (MSK) physicians and scientists highlighted some of the institution’s latest advances in transplantation and cellular therapies at the  Tandem Meetings held February 4 to 6, 2026, in Salt Lake City. The meetings, jointly hosted by the American

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Tuesday, August 17, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Craig Thompson Recognized in City & State’s Life Sciences Power 50 Craig B. Thompson Craig Thompson, MD , President and CEO, was named on the inaugural City & State Life Sciences Power

Scientists are using a molecule from the immune system to combat this serious complication in a new way.

… Friday, January 15, 2016 Summary Graft-versus-host disease (GVHD) is a complication of blood and marrow stem cell transplantation . A new study reveals how the patient’s immune system restores the intestinal lining following damage from GVHD and points to a strategy for a potential therapy to alleviate

Mammography has shortcomings but the price is reasonable; MRI is more effective but expensive. Two new modalities — contrast-enhanced digital mammography (CEDM) and abbreviated breast MRI (AB-MRI) — may provide the best of both.

… Thursday, June 23, 2016 Since the mid-1980s, mammography has been the primary screening modality for breast cancer. While it has reduced mortality rates, there are some notable drawbacks. Mammography fails to detect as many as 30 percent of cancers because overlying normal breast tissue obscures them

MSK’s Integrative Medicine Service focuses on empowering patients with practices — from acupuncture to music therapy — that fit seamlessly into your care plan.

… Thursday, April 10, 2025 A cancer diagnosis can make you feel as if the ground has shifted beneath you, throwing your life into a cycle of appointments, treatments, and scans. It’s common to feel waves of uncertainty or even disconnection from your own body.  MSK’s Integrative Medicine Service empowers

According to a large retrospective study co-led by Memorial Sloan Kettering Cancer Center and published in the Journal of Clinical Oncology, PTCy is an acceptable alternative to CNI-based prophylaxis in MUD HCT recipients and superior for MMUD HCT. These results will help improve minority donor participation in the NMDP registry.

… Wednesday, July 17, 2024 Post-transplantation cyclophosphamide (PTCy) led to similar overall survival (OS) and graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) in patients who received a hematopoietic stem cell transplant (HCT) from a matched unrelated donor (MUD) and those who received

In a recent interview, MSK's Dr. Jeffrey Drebin addressed why it’s important for people to keep up with their routine screenings and not put off cancer treatment or surgery.

… Wednesday, July 15, 2020 Cancer care is essential care and screenings and treatments can’t wait. That was the message that MSK’s Chair of the Department of Surgery, Jeffrey Drebin, MD, PhD , shared during a recent interview with Spectrum News NY1 .  Appearing via Skype with Roma Torre on the New York